Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
Truman J. Milling, Saskia Middeldorp, Lizhen Xu, et al.
Circulation (2023) Vol. 147, Iss. 13, pp. 1026-1038
Open Access | Times Cited: 83

Showing 1-25 of 83 citing articles:

Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage
Stuart J. Connolly, Mukul Sharma, Alexander T. Cohen, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 19, pp. 1745-1755
Closed Access | Times Cited: 79
Anticoagulants: from chance discovery to structure-based design
Noel Chan, Stephanie Carlin, Jack Hirsh
Pharmacological Reviews (2025) Vol. 77, Iss. 2, pp. 100037-100037
Closed Access | Times Cited: 1
Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper
Job Harenberg, Robert C. Gosselin, Adam Cuker, et al.
Thrombosis and Haemostasis (2024) Vol. 124, Iss. 08, pp. 770-777
Open Access | Times Cited: 11
2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery
Annemarie Thompson, Kirsten E. Fleischmann, Nathaniel R. Smilowitz, et al.
Journal of the American College of Cardiology (2024)
Closed Access | Times Cited: 10
Andexanet alfa versus non-specific treatments for intracerebral hemorrhage in patients taking factor Xa inhibitors — Individual patient data analysis of ANNEXA-4 and TICH-NOAC
Bernhard Siepen, Alexandros A. Polymeris, Ashkan Shoamanesh, et al.
International Journal of Stroke (2024) Vol. 19, Iss. 5, pp. 506-514
Closed Access | Times Cited: 9
Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH
Stephanie Carlin, Adam Cuker, A. Gatt, et al.
Journal of Thrombosis and Haemostasis (2024) Vol. 22, Iss. 9, pp. 2653-2669
Open Access | Times Cited: 8
Reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH: R1
Jerrold H. Levy, Joseph R. Shaw, Lana A. Castellucci, et al.
Journal of Thrombosis and Haemostasis (2024) Vol. 22, Iss. 10, pp. 2889-2899
Closed Access | Times Cited: 7
Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study
Paul P. Dobesh, Gregory J. Fermann, Mary J. Christoph, et al.
Research and Practice in Thrombosis and Haemostasis (2023) Vol. 7, Iss. 6, pp. 102192-102192
Open Access | Times Cited: 19
Real-world clinical outcomes among US Veterans with oral factor xa inhibitor–related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate
S. Scott Sutton, Joseph Magagnoli, Tammy H. Cummings, et al.
Journal of Thrombosis and Thrombolysis (2023) Vol. 56, Iss. 1, pp. 137-146
Open Access | Times Cited: 18
Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?
Nicolas Gendron, Paul Billoir, Virginie Siguret, et al.
Thrombosis Research (2024) Vol. 237, pp. 171-180
Open Access | Times Cited: 6
Challenges to Laboratory Monitoring of Direct Oral Anticoagulants
Jesse Qiao, Minh‐Ha Tran
Clinical and Applied Thrombosis/Hemostasis (2024) Vol. 30
Open Access | Times Cited: 5
Association of Anaesthetists guidelines: the use of blood components and their alternatives 2024
Akshay Shah, A. A. Klein, Seema Agarwal, et al.
Anaesthesia (2025)
Open Access
Perioperative Risk: Short Review of Current Approach in Non Cardiac Surgery
Andreea Boghean, Cristian Guțu, Dorel Firescu
Journal of Cardiovascular Development and Disease (2025) Vol. 12, Iss. 1, pp. 24-24
Open Access
Reversal of Direct Oral Anticoagulants (DOACs) for Critical Bleeding or Urgent Procedures
Mark Goldin, Nikolaos Tsaftaridis, Jack Jnani, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 3, pp. 1013-1013
Open Access
JCS/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias
Yu‐ki Iwasaki, Takashi Noda, Masaharu Akao, et al.
Circulation Journal (2025)
Open Access
Results of rapid plasma direct oral anticoagulant levels greatly expand stroke thrombolysis eligibility: evidence from real‐world implementation
Elizabeth Callaly, Jason Tjahyadi, Vicky Yin, et al.
Internal Medicine Journal (2025)
Closed Access
Oral Anticoagulants Beyond Warfarin
Renske H. Olie, Kristien Winckers, Bianca Rocca, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 551-575
Open Access | Times Cited: 13
Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis
C Michael White, Kimberly Snow Caroti, Youssef Bessada, et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (2024) Vol. 44, Iss. 5, pp. 394-408
Open Access | Times Cited: 4
Antidote vs. unspecific hemostatic agents for the management of direct oral anticoagulant-related bleeding in trauma
Jan Wienhold, Farahnaz Rayatdoost, Herbert Schöchl, et al.
Current Opinion in Anaesthesiology (2024) Vol. 37, Iss. 2, pp. 101-109
Closed Access | Times Cited: 3
Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors
Mark Goldin, Kolton Smith, Ioannis Koulas, et al.
TH Open (2024) Vol. 08, Iss. 02, pp. e209-e215
Open Access | Times Cited: 3
Effective application of a direct-acting oral anticoagulants reversal agent in acute type A aortic dissection repair: A case report
Tatsuto Wakami, Naoto Fukunaga, Akio Shimoji, et al.
Asian Cardiovascular and Thoracic Annals (2024) Vol. 32, Iss. 4, pp. 213-214
Closed Access | Times Cited: 2
A framework for managing severe DOAC-related bleeding: Recognize, Reverse, Resume, Reduce
Stéphane Cormier, Deborah Siegal
Thrombosis Update (2024) Vol. 15, pp. 100165-100165
Open Access | Times Cited: 2
Andexanet Alfa–Induced Heparin Resistance: Sustained Anticoagulant Inefficacy Despite Antithrombin Therapy
Kohei Nagashima, Chikara Ueki, Junpei Numari, et al.
Journal of Cardiothoracic and Vascular Anesthesia (2024) Vol. 38, Iss. 8, pp. 1727-1729
Closed Access | Times Cited: 2
Effects of preinjury oral anticoagulants on the outcomes of traumatic brain injury in elderly patients: a systematic review and meta-analysis
Armin Karamian, Ali Seifi, Brandon Lucke‐Wold
Brain Injury (2024) Vol. 38, Iss. 14, pp. 1197-1211
Closed Access | Times Cited: 2
Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management
Claudio Laudani, Davide Capodanno, Dominick J. Angiolillo
Expert Opinion on Drug Safety (2023) Vol. 22, Iss. 12, pp. 1193-1212
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top